Skip to search formSkip to main contentSkip to account menu

AZD 1152

Known as: AZD-1152, AZD1152, Aurora kinase inhibitor AZD1152 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

barasertib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA
Aurora-B kinase overexpression plays important roles in the malignant progression of prostate cancer (PCa). AZD1152-HQPA, as an… 
2016
2016
Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line
Deregulated expression of the Aurora kinases (Aurora-A, B, and C) is thought to be involved in cell malignant transformation and… 
2015
2015
A Novel Therapeutic Combination Sequentially Targeting Aurora B and Bcl-xL in Hepatocellular Carcinoma
ABSTRACTBackgroundEffective therapeutic combinations targeting the oncogenic pathway still are unknown in human hepatocellular… 
2011
2011
Imaging Colon Cancer Response Following Treatment with AZD1152: A Preclinical Analysis of [18F]Fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]Fluorothymidine Imaging
Purpose: To determine whether treatment response to the Aurora B kinase inhibitor, AZD1152, could be monitored early in the… 
2011
2011
Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia
1Erasmus University Medical Center, Rotterdam, The Netherlands; 2Radboud University Nijmegen Medical Centre, Nijmegen, The… 
2011
2011
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
SummaryIntroduction Modeling and simulation of pharmacokinetics and pharmacodynamics has previously been shown to be potentially… 
2009
2009
Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152
AZD1152 is a highly selective Aurora B kinase inhibitor currently undergoing Phase I and II clinical evaluation in patients with… 
2009
2009
Biochemical characterization of GSK 1070916 , a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time 1
Kelly ANDERSON*, Zhihong LAI*, Octerloney B. MCDONALD†, J. Darren STUART‡, Eldridge N. NARTEY‡, Mary Ann HARDWICKE§, Ken… 
2009
2009
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
2008
2008
Preclinical evaluation of M 30 and M 65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity
M30 and M65 are ELISAs that detect different circulating forms of cytokeratin 18. Using the aurora kinase inhibitor AZD1152 and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)